USANA's CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporation's Board of Directors
17 March 2008 - 1:00PM
PR Newswire (US)
LA JOLLA, Calif., March 17 /PRNewswire-FirstCall/ -- Immunosyn
Corporation (OTC:IMYN) (BULLETIN BOARD: IMYN) is pleased to
announce that Myron W. Wentz, Ph.D., Chief Executive Officer and
Chairman of the Board of USANA Health Sciences, Incorporated
(NASDAQ:USNA), was elected to serve as a member of its Board of
Directors. Dr. Wentz will be filling a newly created director
position resulting from the increase in the authorized number of
directors of Immunosyn. "To add to our Board of Directors a Ph.D.
in microbiology and immunology, and an internationally recognized
pioneer in human cell culture technology and infectious disease
diagnoses such as Dr. Wentz with his longstanding successful
business history in our industry, is a significant and synergistic
addition to the leadership of Immunosyn," stated Stephen D.
Ferrone, President and CEO of Immunosyn. "Because Dr. Wentz is a
scientist as well as a highly accomplished businessman, he
understands the significance of SF-1019 from a scientific,
humanitarian and business perspective. His industry background,
knowledge, network, advice and good counsel will be a substantial
benefit to Immunosyn and its shareholders." Dr. Wentz founded USANA
in 1992 and has been the CEO and Chairman since its inception.
USANA is a public company that develops and manufactures high
quality nutritional and personal care products that are sold
directly to Preferred Customers and Associates throughout the
world. The success of USANA's products is largely the result of Dr.
Wentz's insights on cellular nutrition. In 1974, Dr. Wentz founded
Gull Laboratories (the former parent company of USANA) and spent 20
years developing, manufacturing and marketing medical diagnostic
test kits designed to detect infectious diseases, particularly
those caused by viruses. These products were used in private and
hospital laboratories around the world. The most successful of
Gull's products was the first commercially available test for the
diagnosis of infection with the Epstein-Barr virus (EBV). Dr. Wentz
served as President and Chairman of Gull from 1974 to 1994, when he
sold it to Fresenius, a German medical products company. He
continued as Chairman until 1998. In 1998, Dr. Wentz also founded
Sanoviv Medical Institute, a leading-edge holistic medical facility
located on the Pacific Coast near Rosarito Beach, Mexico. "I am
privileged to be asked to contribute my industry knowledge and
experience toward the success of a company such as Immunosyn, whose
dedication to 'identifying, marketing and distributing
biopharmaceuticals derived from biological and natural substances
that work with the body rather than against it,' closely parallels
my life's work," says Dr. Wentz. Dr. Wentz received his Doctorate
from the University of Utah, an MS degree in microbiology from the
University of North Dakota and a BS degree in biology from North
Central College in Illinois. In 1969 Dr. Wentz joined a pathology
group in Peoria, IL where until 1973 he served as the infectious
disease specialist and directed the microbiology and immunology
laboratories for three hospitals in the Peoria area. During his
long and distinguished career in biomedical science, Dr. Wentz has
conducted important research on his own and has guided teams of
researchers in other parts of the world. Throughout this period he
has supported research in the life sciences, extending from the
Cardiology Research Center in Moscow to the Linus Pauling Institute
at Oregon State University. He is a member of numerous scientific
organizations around the world and has written books and published
his research in the fields of infectious and degenerative disease.
In recent years Dr. Wentz has turned his attention to humanitarian
concerns, funding the Wentz Medical Centre and Laboratory in Uganda
and the Wentz Medical Center in Cambodia, both of which serve
children in those countries orphaned by diseases such as malaria
and HIV. He also funded construction of the Wentz Concert Hall and
Fine Arts Center at his North Central College alma mater. Dr.
Wentz's business acumen has been recognized through a Presidential
appointment as an advisor to the SBA and receiving an Ernst &
Young Entrepreneur of the Year Award. In 2007 he received the
Albert Einstein Award for lifelong achievement in science. About
Immunosyn Corporation La Jolla, CA-headquartered Immunosyn
Corporation (IMYN.OTC.BB) plans to market and distribute life
enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder, Argyll
Biotechnologies, LLC, to market, sell and distribute SF-1019, a
compound that was developed from extensive research into Biological
Response Modifiers (BRMs). Argyll Biotechnologies, LLC has
initiated the process for regulatory approval of SF-1019 in several
countries and preparations for clinical trials are underway in both
the US and Europe. Research suggests that SF-1019 has the potential
to affect a number of clinical conditions including complications
from Diabetic Mellitus such as Diabetic Neuropathy (DN) and
diabetic ulcers (DU), auto-immune disorders such as Multiple
Sclerosis (MS) and neurological disorders such as Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex
Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information
on Immunosyn and SF-1019 go to http://www.immunosyn.com/) The above
news release contains forward-looking statements. These statements
are based on assumptions that management believes are reasonable
based on currently available information, and include statements
regarding the intent, belief or current expectations of the Company
and its management. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance, and are subject to a wide range of business risks,
external factors and uncertainties. Actual results may differ
materially from those indicated by such forward-looking statements.
For additional information, please consult the Company's most
recent public filings and Annual Report on Form 10-K for its most
recent fiscal year. The Company assumes no obligation to update the
information contained in this press release, whether as a result of
new information, future events or otherwise. DATASOURCE: Immunosyn
Corporation CONTACT: Bill Kraus or Lisa Baker or Devon Blaine,
+1-310-360-1499, fax, +1-310-360-1498, , for Immunosyn Corporation
Web site: http://www.immunosyn.com/
Copyright